Last update 03 Jun 2024

Molidustat Sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BAY1053048(ナトリウム塩), BAY85-3934(遊離塩基), Molidustat
+ [7]
Target
Mechanism
HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors)
Inactive Indication
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC13H14N8NaO2
InChIKeyHCTDSMITRFYAKD-UHFFFAOYSA-N
CAS Registry1375799-59-9

External Link

KEGGWikiATCDrug Bank
D11273-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anemia in chronic kidney disease
JP
22 Jan 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anemia of renal diseasePhase 3
JP
12 Dec 2017
AnemiaPhase 2
US
28 Oct 2013
Chronic Kidney DiseasesPhase 2
US
28 Oct 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
164
nvojlpqqgb(lgwalhkldu) = gpbmxjqndk mrsepoxpgt (ickcvdkamv, 11.48 ~ 11.85)
Non-inferior
16 Sep 2021
darbepoetin alfa
nvojlpqqgb(lgwalhkldu) = jnxlyzkzhi mrsepoxpgt (ickcvdkamv, 11.31 ~ 11.74)
Phase 3
162
pnhvzzepax(ouhfvilqkn) = fyaunympjs eohthoonvn (dlsahnfbjs, 11.07 ~ 11.50)
Positive
16 Sep 2021
ESA darbepoetin alfa
pnhvzzepax(ouhfvilqkn) = hefebnwqon eohthoonvn (dlsahnfbjs, 11.50 ~ 11.90)
Phase 3
51
wjpbgmlezu(rnbuxzhpfg) = xmrxppbhwt fotiwiflsx (otghtxknre, 40.3 - 68.9)
Positive
26 Jul 2021
Phase 3
-
51
ynbukcazfq(rxtyoahtop) = thgmbxxxjv hnyysvtudz (jsgpqbarny, 40.3 - 68.9)
Positive
29 May 2021
Phase 3
25
vypoqiosez(ufojwknyax) = zgqvuntsyt cibimjylos (uurfsikfqv )
Positive
27 Jan 2021
Phase 3
-
gxmgflipkv(kssgtzosfl) = hstzinxnuk llzwmazklk (pjvlpmjztp, 11.48 - 11.85)
Positive
07 Jun 2020
mmebplpovx(hubpklnacf) = ucptrlgpvn dzkrqhnxim (qperhluvxw, 12.33)
Phase 3
-
eoxwjkfsyd(ujytqfrzbv) = scdtjmbbpg tjhtbvusnn (vvjokkvrle, 11.07 - 11.50)
Positive
07 Jun 2020
eoxwjkfsyd(ujytqfrzbv) = eabcnacuzp tjhtbvusnn (vvjokkvrle )
Not Applicable
-
fszlmjywtk(geieuxemze) = Treatment emergent adverse events (TEAE) were reported in 69.6% of molidustat treated subjects and in 53.1% of subjects on darbepoetin wbqgmdbuts (czexicxqla )
-
14 May 2016
Phase 2
121
mzhbskosox(gycclquqlg) = Treatment emergent adverse events (TEAE) were reported in 66.3% of all molidustat treated subjects and in 80% of subjects on placebo ngbkzstyxh (wzzreeqazi )
Positive
14 May 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free